Elexacaftor, in combination with tezacaftor and ivacaftor (marketed as Trikafta), is approved for use in pediatric patients aged 6 years and older who have at least one F508del mutation in the CFTR gene. This makes a significant portion of the CF population eligible for this treatment. Clinical trials have shown that this combination therapy can improve lung function, reduce pulmonary exacerbations, and enhance quality of life for these patients.
